RxDoctor Payments DataLook up a doctor →

Adam Bressler, MD

Infectious Disease · Gainesville, GANPI 1154371870

Payments from drug & device makers

$117,444in general payments, 2019–2025

Across 459 payments — averaging $255.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$85K
  • Emergent Biosolutions Inc.$8K
  • GSK$7K
  • AbbVie$6K
  • Cumberland Pharmaceuticals, Inc.$4K
  • Viiv Healthcare Company$2K
  • plus $5K from 34 others

What the payments were for

  • Consulting fees$6,5106%
  • Speaking & faculty fees$78,86377%
  • Travel & lodging$6,7517%
  • Food & beverage$10,00010%
  • Education$2160%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$117,444 in reported general payments places this provider in the 85th percentile of 260 infectious disease providers in Georgia.

See all infectious disease providers in Georgia

Medicare billing

Part B allowed, 2024
$64,831
Medicare patients
187
Services billed
572

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala84$376,696
OdefseyEmtricitab/Rilpiviri/Tenof Ala30$165,653
JulucaDolutegravir/Rilpivirine35$132,689
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf19$113,520
DovatoDolutegravir Sodium/Lamivudine24$98,161
CabenuvaCabotegravir/Rilpivirine14$91,969
TriumeqAbacavir/Dolutegravir/Lamivudi22$79,926
TivicayDolutegravir Sodium20$56,255
PrezcobixDarunavir/Cobicistat19$49,407
Isentress HdRaltegravir Potassium11$22,300
ErtapenemErtapenem Sodium12$6,193
CeftriaxoneCeftriaxone Sodium25$4,073
Cefazolin Sodium18$1,652
Minocycline Hcl29$1,286
Methenamine Hippurate11$726

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyJuluca, Dovato, Cabenuva, Triumeq, Tivicay$1,536$459,000115 claims
GileadBiktarvy$84,994$376,69684 claims
Janssen Products, LPSymtuza$59$113,52019 claims
Johnson & JohnsonPrezcobix$246$49,40719 claims
MerckIsentress Hd$559$22,30011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 260 infectious disease providers in Georgia.

Other infectious disease in Gainesville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →